← Indications
Landscape

Auditory Neuropathy

Auditory Neuropathy has 6 tracked records across 6 named organizations, including 5 strong-evidence records and 5 active programs. Records with caveats and trial-derived candidates remain visible for deeper review.

Open filtered programs
6
Pipeline Records
strong evidence + caveats + candidates
5
Strong Evidence
1 checked records with caveats
5
Active Programs
currently active
1
Marketed / Approved
commercial or approved
6
Organizations
companies, sponsors, and institutions
Competitive Density
17/100
organization breadth + program volume
Pipeline Velocity
63/100
active and late-stage share
Evidence Coverage
83/100
share strong evidence
Completion Signal
33/100
late-stage, approved, or marketed
Attrition Rate
0/100
share discontinued
Concentration
17/100
top-organization share

Programs by Stage

Preclinical1 · 17%
Phase 1/23 · 50%
Phase 21 · 17%
Approved1 · 17%

Trial / Program Status

Active5 · 83%
Approved1 · 17%

Modality Breakdown

Gene Therapy4 · 67%
Cell Therapy2 · 33%

Program Types

Therapeutic6 · 100%

Top Organizations

Eli Lilly and Company1 · 17%
Lineage Cell Therapeutics1 · 17%
Regeneron Pharmaceuticals1 · 17%
Rinri Therapeutics1 · 17%
Sensorion1 · 17%
Shanghai EuHearing Therapeutics Co., Ltd1 · 17%

Population Tags

adult4 · 67%
bilateral4 · 67%
congenital4 · 67%
genetic4 · 67%
otof-dfnb94 · 67%
pediatric4 · 67%
pre-lingual3 · 50%
profound3 · 50%
auditory-neuropathy2 · 33%
age-related1 · 17%